Optoacoustic Tomography for Head and Neck Cancer
(OUSCCMOTORX Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests the safety and effectiveness of a new imaging device called Multispectral Optoacoustic Tomography (MSOT). The device helps doctors better visualize lymph nodes in the neck that might be affected by certain head and neck cancers. Participants will undergo either surgery or radiotherapy to treat their cancer. Those with confirmed head and neck squamous cell cancer who are planning for surgery or radiotherapy might be suitable for this trial. As an unphased trial, this study offers participants the chance to contribute to groundbreaking research that could enhance cancer imaging techniques.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that the Multispectral Optoacoustic Tomography device is safe for assessing neck lymph nodes in head and neck cancer patients?
Research has shown that Multispectral Optoacoustic Tomography (MSOT) is generally safe and well-tolerated by patients. Studies have investigated its use for diagnosing solid tumors, and no serious side effects have been reported. This procedure uses sound waves and light to create detailed images, making it non-invasive and free of radiation. Other trials have monitored skin temperature before and after using MSOT to ensure safety, and the results have been reassuring. Although researchers continue to study this imaging technique, current evidence suggests it is a safe option for examining lymph nodes in cancer patients.12345
Why are researchers excited about this trial?
Researchers are excited about Multispectral Optoacoustic Tomography (MSOT) for head and neck cancer because it offers a new, non-invasive imaging technique that provides real-time, high-resolution images of tumors. Unlike standard imaging methods like CT or MRI, MSOT uses laser-induced ultrasound signals to visualize the tumor's structure and blood vessels, potentially allowing for earlier and more precise detection of cancerous tissues. This could lead to more targeted and effective treatment plans, minimizing unnecessary damage to healthy tissue and improving patient outcomes. Moreover, the ability to monitor changes during treatments like surgery or radiotherapy could enhance safety and effectiveness, making it a promising tool in the fight against head and neck cancers.
What evidence suggests that the Multispectral Optoacoustic Tomography device is effective for identifying affected lymph nodes in head and neck cancer?
Research has shown that Multispectral Optoacoustic Tomography (MSOT) can help identify and evaluate lymph nodes affected by head and neck cancer. MSOT uses light and sound to create detailed tissue images, potentially offering more accuracy than traditional methods. In past studies, MSOT successfully produced clear images of lymph nodes in oral cancer patients, aiding doctors in assessing cancer spread. This trial will involve two groups: one of surgery patients and another of radiotherapy patients, both imaged using the MSOT device. This technology could enhance treatment planning by providing better information about the cancer. Although interest in MSOT is growing, more research is needed to fully understand its effectiveness in treating head and neck cancer.12678
Who Is on the Research Team?
Christina Henson, MD
Principal Investigator
University of Oklahoma
Are You a Good Fit for This Trial?
This trial is for patients with metastatic head and neck squamous cell carcinomas. Specific eligibility criteria are not provided, but typically participants would need to have the condition under study and meet certain health requirements.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Pre-surgery Imaging (Arm 1)
MSOT imaging is performed on patients prior to surgery to assess lymph nodes and tumor margins.
Radiotherapy Imaging (Arm 2)
MSOT imaging is performed before, during, and after radiotherapy to assess lymph nodes and tumor margins.
Follow-up
Participants are monitored for radiation induced fibrosis using MSOT imaging every 6 months for 2 years.
What Are the Treatments Tested in This Trial?
Interventions
- Multispectral Optoacoustic Tomography
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Oklahoma
Lead Sponsor